DTP|01        |Inactive|DTAP|107
OPV, trivalent|02        |Inactive|POLIO|89
MMR|03        |Active|MMR|03
M/R|04        |Inactive|MMR|03
measles|05        |Inactive|MMR|03
rubella|06        |Inactive|MMR|03
mumps|07        |Inactive|MMR|03
Hep B, adolescent or pediatric|08        |Active|HepB|45
Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed|09        |Active|Td|139
IPV|10        |Active|POLIO|89
pneumococcal conjugate PCV 7|100       |Inactive|PneumoPCV|152
typhoid, ViCPs|101       |Active|TYPHOID|91
DTP-Hib-Hep B|102       |Non-US|HIB|17
DTP-Hib-Hep B|102       |Non-US|DTAP|107
DTP-Hib-Hep B|102       |Non-US|HepB|45
meningococcal C conjugate|103       |Inactive|MENING|108
Hep A-Hep B|104       |Active|HepA|85
Hep A-Hep B|104       |Active|HepB|45
vaccinia (smallpox) diluted|105       |Inactive|Orthopoxvirus|325
DTaP, 5 pertussis antigens|106       |Active|DTAP|107
DTaP, unspecified formulation|107       |Inactive|DTAP|107
meningococcal ACWY, unspecified formulation|108       |Inactive|MENING|108
pneumococcal, unspecified formulation|109       |Inactive|PneumoPCV|152
pneumococcal, unspecified formulation|109       |Inactive|PneumoPPV|33
DTaP-Hep B-IPV|110       |Active|DTAP|107
DTaP-Hep B-IPV|110       |Active|HepB|45
DTaP-Hep B-IPV|110       |Active|POLIO|89
Influenza, live, trivalent, intranasal, PF|111       |Active|FLU|88
Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed|113       |Active|Td|139
meningococcal MCV4P|114       |Active|MENING|108
Tdap|115       |Active|TDAP|115
rotavirus, pentavalent|116       |Active|ROTAVIRUS|122
HPV, bivalent|118       |Inactive|HPV|137
rotavirus, monovalent|119       |Active|ROTAVIRUS|122
DTaP-Hib-IPV|120       |Active|DTAP|107
DTaP-Hib-IPV|120       |Active|POLIO|89
DTaP-Hib-IPV|120       |Active|HIB|17
zoster live|121       |Inactive|ZOSTER|188
rotavirus, unspecified formulation|122       |Inactive|ROTAVIRUS|122
influenza, H5N1-1203|123       |Inactive|H5N1 flu|123
Novel Influenza-H1N1-09, nasal|125       |Inactive|H1N1 flu|128
Novel influenza-H1N1-09, preservative-free|126       |Inactive|H1N1 flu|128
Novel influenza-H1N1-09|127       |Inactive|H1N1 flu|128
Novel Influenza-H1N1-09, all formulations|128       |Inactive|H1N1 flu|128
Japanese Encephalitis, unspecified formulation|129       |Inactive|Japanese encephalitis|129
DTaP-IPV|130       |Active|POLIO|89
DTaP-IPV|130       |Active|DTAP|107
DTaP-IPV-HIB-HEP B, historical|132       |Inactive|DTAP|107
DTaP-IPV-HIB-HEP B, historical|132       |Inactive|HIB|17
DTaP-IPV-HIB-HEP B, historical|132       |Inactive|POLIO|89
DTaP-IPV-HIB-HEP B, historical|132       |Inactive|HepB|45
Pneumococcal conjugate PCV 13|133       |Active|PneumoPCV|152
Japanese Encephalitis IM|134       |Active|Japanese encephalitis|129
Influenza, high-dose, trivalent, PF|135       |Active|FLU|88
Meningococcal MCV4O|136       |Active|MENING|108
HPV, unspecified formulation|137       |Inactive|HPV|137
Td (adult)|138       |Inactive|Td|139
Td(adult) unspecified formulation|139       |Inactive|Td|139
Influenza, split virus, trivalent, PF|140       |Active|FLU|88
Influenza, split virus, trivalent, preservative|141       |Active|FLU|88
Adenovirus types 4 and 7|143       |Active|ADENO|82
influenza, seasonal, intradermal, preservative free|144       |Inactive|FLU|88
DTaP,IPV,Hib,HepB|146       |Active|DTAP|107
DTaP,IPV,Hib,HepB|146       |Active|HIB|17
DTaP,IPV,Hib,HepB|146       |Active|HepB|45
DTaP,IPV,Hib,HepB|146       |Active|POLIO|89
meningococcal MCV4, unspecified formulation|147       |Inactive|MENING|108
Meningococcal C/Y-HIB PRP|148       |Inactive|MENING|108
Meningococcal C/Y-HIB PRP|148       |Inactive|HIB|17
Influenza, live, quadrivalent, intranasal|149       |Active|FLU|88
influenza, split (incl. purified surface antigen)|15        |Inactive|FLU|88
Influenza, split virus, quadrivalent, PF|150       |Active|FLU|88
influenza nasal, unspecified formulation|151       |Inactive|FLU|88
Pneumococcal Conjugate, unspecified formulation|152       |Inactive|PneumoPCV|152
Influenza, MDCK, trivalent, PF|153       |Active|FLU|88
Influenza, recombinant, trivalent, PF|155       |Active|FLU|88
Influenza, split virus, quadrivalent, preservative|158       |Active|FLU|88
influenza, whole|16        |Inactive|FLU|88
Influenza A monovalent (H5N1), ADJUVANTED-2013|160       |Active|H5N1 flu|123
Influenza, injectable,quadrivalent, preservative free, pediatric|161       |Active|FLU|88
meningococcal B, recombinant|162       |Active|MeningB|164
meningococcal B, OMV|163       |Active|MeningB|164
meningococcal B, unspecified|164       |Inactive|MeningB|164
HPV9|165       |Active|HPV|137
influenza, intradermal, quadrivalent, preservative free|166       |Inactive|FLU|88
Influenza, adjuvanted, trivalent, PF|168       |Active|FLU|88
Hib, unspecified formulation|17        |Inactive|HIB|17
DTAP/IPV/HIB - non-US|170       |Non-US|POLIO|89
DTAP/IPV/HIB - non-US|170       |Non-US|HIB|17
DTAP/IPV/HIB - non-US|170       |Non-US|DTAP|107
Influenza, MDCK, quadrivalent, PF|171       |Active|FLU|88
cholera, WC-rBS|172       |Non-US|cholera|26
cholera, BivWC|173       |Non-US|cholera|26
cholera, live attenuated|174       |Active|cholera|26
Rabies - IM Diploid cell culture|175       |Active|RABIES|90
Rabies - IM fibroblast culture|176       |Active|RABIES|90
PCV10|177       |Non-US|PneumoPCV|152
rabies, intramuscular injection|18        |Inactive|RABIES|90
Yellow fever vaccine live - alt|183       |Active|YELLOWFEVER|184
Yellow fever, unspecified|184       |Inactive|YELLOWFEVER|184
Influenza, recombinant, quadrivalent, PF|185       |Active|FLU|88
Influenza, MDCK, quadrivalent, preservative|186       |Active|FLU|88
zoster recombinant|187       |Active|ZOSTER|188
zoster, unspecified formulation|188       |Inactive|ZOSTER|188
HepB-CpG|189       |Active|HepB|45
BCG|19        |Active|BCG|19
Hep A-Hep B, pediatric/adolescent|193       |Non-US|HepB|45
Hep A-Hep B, pediatric/adolescent|193       |Non-US|HepA|85
Influenza, Southern Hemisphere|194       |Inactive|FLU|88
DT, IPV adsorbed|195       |Non-US|POLIO|89
DT, IPV adsorbed|195       |Non-US|Td|139
Td, adsorbed, preservative free, adult use, Lf unspecified|196       |Active|Td|139
Influenza, high-dose, quadrivalent, PF|197       |Active|FLU|88
DTaP|20        |Active|DTAP|107
influenza, Southern Hemisphere, pediatric, preservative free|200       |Active|FLU|88
Influenza, Southern Hemisphere, quadrivalent, PF|201       |Active|FLU|88
influenza, Southern Hemisphere, quadrivalent, with preservative|202       |Active|FLU|88
meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)|203       |Active|MENING|108
Ebola Zaire vaccine, live, recombinant, 1mL dose|204       |Active|Ebola|214
Influenza, adjuvanted, quadrivalent, PF|205       |Active|FLU|88
Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection|206       |Active|Orthopoxvirus|325
COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose|207       |Inactive|COVID-19|213
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose|208       |Inactive|COVID-19|213
varicella|21        |Active|VARICELLA|21
COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL|210       |Non-US|COVID-19|213
COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL|211       |Inactive|COVID-19|213
COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL|212       |Inactive|COVID-19|213
SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED|213       |Inactive|COVID-19|213
Ebola, unspecified|214       |Inactive|Ebola|214
Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF|215       |Active|PneumoPCV|152
Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF|216       |Active|PneumoPCV|152
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose|217       |Inactive|COVID-19|213
COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose|218       |Inactive|COVID-19|213
COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose|219       |Inactive|COVID-19|213
DTP-Hib|22        |Inactive|DTAP|107
DTP-Hib|22        |Inactive|HIB|17
HepB recombinant, 3-antigen, Al(OH)3|220       |Inactive|HepB|45
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose|221       |Inactive|COVID-19|213
Tick-borne encephalitis, unspecified|222       |Inactive|Tick-borne encephalitis|222
Tick-borne encephalitis, inactivated, PF, 0.25mL|223       |Active|Tick-borne encephalitis|222
Tick-borne encephalitis, inactivated, PF, 0.5mL|224       |Active|Tick-borne encephalitis|222
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL|225       |Never Active|COVID-19|213
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL|226       |Never Active|COVID-19|213
COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose|227       |Inactive|COVID-19|213
COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose|228       |Inactive|COVID-19|213
COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose|229       |Inactive|COVID-19|213
plague|23        |Inactive|Plague|23
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL|230       |Inactive|COVID-19|213
influenza, Southern Hemisphere, high-dose, quadrivalent|231       |Active|FLU|88
Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis|24        |Active|ANTHRAX|319
typhoid, oral|25        |Active|TYPHOID|91
cholera, unspecified formulation|26        |Inactive|cholera|26
DT (pediatric)|28        |Inactive|DTAP|107
COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose|300       |Inactive|COVID-19|213
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose|301       |Inactive|COVID-19|213
COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose|302       |Inactive|COVID-19|213
RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF|303       |Active|RSV|304
Respiratory syncytial virus (RSV), unspecified|304       |Inactive|RSV|304
RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF|305       |Active|RSV|304
RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months|306       |Active|RSV|304
RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months|307       |Active|RSV|304
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL|308       |Inactive|COVID-19|213
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL|309       |Active|COVID-19|213
Hep A, pediatric, unspecified formulation|31        |Inactive|HepA|85
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL|310       |Active|COVID-19|213
COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL|311       |Active|COVID-19|213
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL|312       |Active|COVID-19|213
COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL|313       |Active|COVID-19|213
Respiratory syncytial virus (RSV) vaccine, unspecified|314       |Inactive|RSV|304
Respiratory syncytial virus (RSV) MAB, unspecified|315       |Inactive|RSV|304
Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF|316       |Active|MENING|108
Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF|316       |Active|MeningB|164
Chikungunya live attenuated vaccine, 0.5 mL, PF|317       |Active|Chikungunya|317
Anthrax, post-exposure prophylaxis|318       |Active|ANTHRAX|319
Anthrax vaccine, unspecified|319       |Inactive|ANTHRAX|319
meningococcal MPSV4|32        |Inactive|MENING|108
Influenza, MDCK, trivalent, preservative|320       |Active|FLU|88
Influenza-avian, H5N8, monovalent, PF|321       |Active|FLU-Avian-H5|323
Influenza-avian, H5N8, monovalent, preservative|322       |Active|FLU-Avian-H5|323
Influenza-avian, H5, unspecified formulation|323       |Inactive|FLU-Avian-H5|323
Poliovirus, inactivated, fractional-dose (fIPV)|324       |Non-US|POLIO|89
Vaccinia (smallpox, monkeypox), unspecified|325       |Inactive|Orthopoxvirus|325
RSV, mRNA, injectable, PF|326       |Active|RSV|304
Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF|327       |Active|PneumoPCV|152
Meningococcal oligosaccharide (MenACWY), (MenB), PF|328       |Active|MeningB|164
Meningococcal oligosaccharide (MenACWY), (MenB), PF|328       |Active|MENING|108
Chikungunya, VLP, recombinant, 0.8 mL, PF|329       |Active|Chikungunya|317
pneumococcal polysaccharide PPV23|33        |Active|PneumoPPV|33
Dengue fever, unspecified|330       |Inactive|DENGUE|330
Influenza, Southern Hemisphere, trivalent, PF|331       |Active|FLU|88
RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF|332       |Active|RSV|304
Influenza, live, trivalent, intranasal, self/caregiver admin, PF|333       |Active|FLU|88
COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL|334       |Active|COVID-19|213
Influenza, Southern Hemisphere, high-dose, trivalent, PF|337       |Active|FLU|88
Influenza, mRNA, trivalent, PF|338       |Active|FLU|88
tetanus toxoid, adsorbed|35        |Inactive|Td|139
yellow fever live|37        |Active|YELLOWFEVER|184
rubella/mumps|38        |Inactive|MMR|03
Japanese encephalitis SC|39        |Inactive|Japanese encephalitis|129
rabies, intradermal injection|40        |Inactive|RABIES|90
typhoid, parenteral|41        |Inactive|TYPHOID|91
Hep B, adolescent/high risk infant|42        |Inactive|HepB|45
Hep B, adult|43        |Active|HepB|45
Hep B, high-dosage, dialysis or IC|44        |Active|HepB|45
Hep B, unspecified formulation|45        |Inactive|HepB|45
Hib (PRP-D)|46        |Inactive|HIB|17
Hib (HbOC)|47        |Inactive|HIB|17
Hib (PRP-T)|48        |Active|HIB|17
Hib (PRP-OMP)|49        |Active|HIB|17
DTaP-Hib|50        |Inactive|HIB|17
DTaP-Hib|50        |Inactive|DTAP|107
COVID-19 Non-US Vaccine, UNSPECIFIED|500       |Non-US|COVID-19|213
COVID-19 IV Non-US Vaccine (QAZCOVID-IN)|501       |Non-US|COVID-19|213
COVID-19 IV Non-US Vaccine (COVAXIN)|502       |Non-US|COVID-19|213
COVID-19 LAV Non-US Vaccine (COVIVAC)|503       |Non-US|COVID-19|213
COVID-19 VVnr Non-US Vaccine (Sputnik Light)|504       |Non-US|COVID-19|213
COVID-19 VVnr Non-US Vaccine (Sputnik V)|505       |Non-US|COVID-19|213
COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology|506       |Non-US|COVID-19|213
COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)|507       |Non-US|COVID-19|213
COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)|508       |Non-US|COVID-19|213
COVID-19 PS Non-US Vaccine (EpiVacCorona)|509       |Non-US|COVID-19|213
Hib-Hep B|51        |Inactive|HIB|17
Hib-Hep B|51        |Inactive|HepB|45
COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)|510       |Non-US|COVID-19|213
COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)|511       |Non-US|COVID-19|213
SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz)|512       |Non-US|COVID-19|213
SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax)|513       |Non-US|COVID-19|213
SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D)|514       |Non-US|COVID-19|213
SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901)|515       |Non-US|COVID-19|213
COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)|516       |Non-US|COVID-19|213
SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)|517       |Non-US|COVID-19|213
COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)|518       |Non-US|COVID-19|213
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna|519       |Non-US|COVID-19|213
Hep A, adult|52        |Active|HepA|85
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech|520       |Non-US|COVID-19|213
COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK|521       |Non-US|COVID-19|213
typhoid, parenteral, AKD (U.S. military)|53        |Inactive|TYPHOID|91
adenovirus, type 4|54        |Inactive|ADENO|82
adenovirus, type 7|55        |Inactive|ADENO|82
dengue fever tetravalent|56        |Active|DENGUE|330
HPV, quadrivalent|62        |Active|HPV|137
Lyme disease|66        |Inactive|Lyme disease|66
rotavirus, tetravalent|74        |Inactive|ROTAVIRUS|122
Vaccinia (smallpox, monkeypox), live|75        |Active|Orthopoxvirus|325
Tick-borne encephalitis vaccine (non-US)|77        |Non-US|Tick-borne encephalitis|222
VEE, live|80        |Inactive|VEE|92
VEE, inactivated|81        |Inactive|VEE|92
adenovirus, unspecified formulation|82        |Inactive|ADENO|82
Hep A, ped/adol, 2 dose|83        |Active|HepA|85
Hep A, ped/adol, 3 dose|84        |Inactive|HepA|85
Hep A, unspecified formulation|85        |Inactive|HepA|85
influenza, unspecified formulation|88        |Inactive|FLU|88
polio, unspecified formulation|89        |Inactive|POLIO|89
rabies, unspecified formulation|90        |Inactive|RABIES|90
typhoid, unspecified formulation|91        |Inactive|TYPHOID|91
VEE, unspecified formulation|92        |Inactive|VEE|92
MMRV|94        |Active|MMR|03
MMRV|94        |Active|VARICELLA|21
